Premium
Effects of fluosol‐DA and oxygen breathing on adriamycin antitumor activity and cardiac toxicity in mice
Author(s) -
Teicher Beverly A.,
Holden Sylvia A.,
Crawford James M.
Publication year - 1988
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19880601)61:11<2196::aid-cncr2820611112>3.0.co;2-t
Subject(s) - medicine , cardiac toxicity , oxygen toxicity , toxicity , oxygen , pharmacology , anesthesia , lung , chemistry , organic chemistry
Tumor growth delays were obtained in the MX1 human breast carcinoma xenograft treated with various combinations of Adriamycin (doxorubicin), Fluosol‐DA, and carbogen breathing (95% oxygen/5% carbon dioxide). Adding carbogen breathing (6 hours) or Fluosol‐DA (Green Cross, Osaka, Japan) and air breathing to this drug treatment did not change the tumor growth delay observed. When 2 hours of carbogen breathing was delivered immediately after injection with Fluosol‐DA and Adriamycin, a tumor growth delay of almost 36 days was observed, which was a significant increase from the tumor growth delay obtained with Adriamycin alone ( P < 0.01). Increasing the carbogen breathing time to 6 hours immediately after drug administration resulted in a tumor growth delay of about 43 days which was not statistically significantly different from the tumor growth delay seen with the complete treatment and 2 hours of carbogen breathing, but was different from the drug alone ( P < 0.005). A morphologic evaluation of Adriamycin cardiotoxicity in combination with Fluosol‐DA and carbogen breathing was carried out. There was only mild cardiotoxicity in all treatment groups. There was a trend towards increased cardiotoxicity of Adriamycin as the treatment dose was increased from 1 to 4 mg/kg/dose, reaching statistical significance ( P < 0.05) for the Adriamycin (4 mg/kg/dose) + Fluosol‐DA + carbogen breathing group when compared to the three treatment groups at 1 mg/kg/dose Adriamycin. The results of these studies indicate that there may be a therapeutic gain by the use of Fluosol‐DA and carbogen breathing in combination with Adriamycin chemotherapy.